197 related articles for article (PubMed ID: 27036356)
1. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
Rex JH; Outterson K
Lancet Infect Dis; 2016 Apr; 16(4):500-5. PubMed ID: 27036356
[TBL] [Abstract][Full Text] [Related]
2. Repairing the broken market for antibiotic innovation.
Outterson K; Powers JH; Daniel GW; McClellan MB
Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
[TBL] [Abstract][Full Text] [Related]
3. Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
Edwards SE; Morel CM
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):685-692. PubMed ID: 31847613
[No Abstract] [Full Text] [Related]
4. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
[TBL] [Abstract][Full Text] [Related]
5. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
Kesselheim AS; Outterson K
Health Aff (Millwood); 2010 Sep; 29(9):1689-96. PubMed ID: 20820028
[TBL] [Abstract][Full Text] [Related]
6. The antibiotic pipeline: reviving research and development and speeding drugs to market.
Luepke KH; Mohr JF
Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
[TBL] [Abstract][Full Text] [Related]
7. Overcoming the current deadlock in antibiotic research.
Schäberle TF; Hack IM
Trends Microbiol; 2014 Apr; 22(4):165-7. PubMed ID: 24698433
[TBL] [Abstract][Full Text] [Related]
8. Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality.
Outterson K; Gopinathan U; Clift C; So AD; Morel CM; Røttingen JA
PLoS Med; 2016 Jun; 13(6):e1002043. PubMed ID: 27299990
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic research and development: business as usual?
Harbarth S; Theuretzbacher U; Hackett J;
J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
[TBL] [Abstract][Full Text] [Related]
10. Novel approaches are needed to develop tomorrow's antibacterial therapies.
Spellberg B; Bartlett J; Wunderink R; Gilbert DN
Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
[TBL] [Abstract][Full Text] [Related]
11. Drug development: Time for teamwork.
May M
Nature; 2014 May; 509(7498):S4-5. PubMed ID: 24784427
[No Abstract] [Full Text] [Related]
12. Is the GAIN Act a turning point in new antibiotic discovery?
Brown ED
Can J Microbiol; 2013 Mar; 59(3):153-6. PubMed ID: 23540332
[TBL] [Abstract][Full Text] [Related]
13. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
White AR;
J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625
[TBL] [Abstract][Full Text] [Related]
14. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
Brogan DM; Mossialos E
Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
[TBL] [Abstract][Full Text] [Related]
15. Report urges controversial 'delinkage' to foster new antibiotics.
Holmes D
Nat Med; 2014 Apr; 20(4):320. PubMed ID: 24710363
[No Abstract] [Full Text] [Related]
16. Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics.
Lum K; Bhatti T; Holland S; Guthrie M; Sassman S
J Law Med Ethics; 2018 Jun; 46(1_suppl):66-74. PubMed ID: 30146960
[TBL] [Abstract][Full Text] [Related]
17. Countries mull over incentives for developing antibiotics.
Anderson T
Lancet; 2016 May; 387(10031):1894-5. PubMed ID: 27203638
[No Abstract] [Full Text] [Related]
18. What are the economic barriers of antibiotic R&D and how can we overcome them?
Renwick M; Mossialos E
Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
[No Abstract] [Full Text] [Related]
19. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
Outterson K; McDonnell A
Health Aff (Millwood); 2016 May; 35(5):784-90. PubMed ID: 27140983
[TBL] [Abstract][Full Text] [Related]
20. Towards new business models for R&D for novel antibiotics.
So AD; Gupta N; Brahmachari SK; Chopra I; Munos B; Nathan C; Outterson K; Paccaud JP; Payne DJ; Peeling RW; Spigelman M; Weigelt J
Drug Resist Updat; 2011 Apr; 14(2):88-94. PubMed ID: 21439891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
